Sialic acids, commonly present as terminal carbohydrates on glycoconjugates, are essential for a variety of cellular functions including cell adhesion and signal recognition as well as the formation and progression of tumors.{16261} Disruption of sialic acid biosynthesis can result in severe glomerular proteinuria or neuromuscular disorders such as hereditary inclusion body myopathy (HIBM).{16263} N-Acetyl-D-mannosamine (ManNAc) is the precursor of all physiological sialic acids. Intraperitoneal injection of ManNAc twice daily at 1,000 mg/kg in C57BL/6 mice for 13 days leads to increased sialylation in kidney, liver, blood cells, brain, spinal cord, muscle, heart, lung, and spleen.{16262} ManNAc reverses hyposialylation and improves glomerular integrity in GneM712T/M712T mice whose key enzyme for sialic acid production has been deleted and may prove therapeutic in the treatment of HIBM.{16263}
Available on backorder
A precursor of sialic acid that increases sialylation in kidney, liver, blood cells, brain, spinal cord, muscle, heart, lung, and spleen
Formal name: 2-(acetylamino)-2-deoxy-β-D-mannopyranose
Synonyms: ManNAc
Molecular weight: 221.2
CAS: 7772-94-3
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals||Research Area|Cell Biology|Cytoskeleton & Motor Proteins
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
The nuclear factor-κB (NF-κB) regulates the expression of numerous genes involved in immunity and inflammation, cellular stress responses, growth, and apoptosis. Resveratrol, a polyphenolic trans-stilbene, is a known inhibitor of the activation of NF-κB and exhibits activity against a wide variety of cancer cells. CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}
Available on backorder